Dr. Hui-Ming Chang is a cross-discipline physician scientist with academic leadership experience in research, administration, education, and clinical medicine. She received her medical degree from National Taiwan University, master of public health in Epidemiology and master of science in Physiology from Harvard Chan School of Public Health. Her post-graduate trainings include internship at George Washington University Medical Center, residency at Boston University Medical Center, and clinical and research fellowship at Harvard Medical School, Boston Children’s Hospital. Dr. Chang came to UAMS from University of Missouri School of Medicine where she was co-director of the Center for Precision Medicine. Prior to U. of Missouri, she was faculty at Harvard Medical School, Massachusetts General Hospital, U. of Texas MD Anderson Cancer Center, and U. of Texas Health Science Center at Houston. Her prior academic positions include vice president for international programs and special advisor to the president at the U. of Texas Health Science Center at Houston, director of senior clinical performance examination at U. of Texas Houston Medical School, and director of education, Department of Palliative Care and Rehabilitation at U. of Texas MD Anderson Cancer Center.

Her services on national and institutional committees include Board of Directors of the American Academy of Pain Medicine, Task Force for clinical practice guidelines-cancer pain management of the American Society of Anesthesiologists, Executive Council of the U. of Texas at Houston, Search Committee for President of the U. of Texas at Houston, and scientific advisory committee of the university clinical research center at the U. of Texas at Houston and M.D. Anderson Cancer Center. She was the recipient of Fleming and Davenport award and medical honoree of American Heart Association Houston Heart Ball. She was nominated for Councilor position, alumni association of Harvard Chan School of Public Health in 2020.
Her contributions to medical sciences include opioid effects on evoked substance P release from primary sensory neurons, co-authoring the discovery of SUMO/Sentrin, and the cloning of Class H defect in Glycosylphosphatidylinositol Anchor. Recently she devoted majority of her time on onco-cardiology (cardio-oncology). With her cross-discipline expertise in epidemiology, evidence-based medicine, and basic research, she translated bench laboratory data to bedside clinical trials for prevention of doxorubicin-induced cardiotoxicity. This investigator initiated clinical trials received 3.48 million NIH RO1 award, HL 151993, 6/2020-5/2025.

Co-Director 2016-2020
Center for Precision Medicine
University of Missouri
Columbia, MO

Special Advisor to the President 2001-2008
University of Texas Health Science Center at Houston
Houston, TX

Vice President 2006-2008
International Programs
University of Texas Health Science Center at Houston Houston, TX

Associate Vice President of International Programs 2001-2006
University of Texas Health Science Center at Houston
Houston, TX

Director of Education 2000-2003
Department of Palliative Care and Rehabilitation
University of Texas, M.D. Anderson Cancer Center
Houston, TX

Course Director 1997-2003
Senior Clinical Rotation
(Palliative Care, Pain Management and Symptom Control)
University of Texas Medical School at Houston
University of Texas, M.D. Anderson Cancer Center
Houston, TX

Director 1996-2001
Senior Clinical Performance Examination
(Standardized Patient OSCE Examination)
University of Texas Medical School at Houston
Houston, TX